Theodore (Ted) Schenkelberg, M.B.A., M.P.H., brings more than 20 years of experience advancing biomedical and global health priorities across the nonprofit and for-profit sectors. He is co-founder of the Human Immunome Project where he currently serves as Senior Vice President and Chief Strategy Officer.

Previously, Schenkelberg worked as a strategic consultant in the global health and biotech space, including work for a leading Indian health system and national initiatives on reproductive health and antibiotic resistance. He served for more than seven years as a Director at the International AIDS Vaccine Initiative (IAVI) where he played a key role in building a $50 million global vaccine design program.

Schenkelberg brings strong private sector experience having worked as a licensed health and technology analyst at Carnegie Capital, an investment firm with more than $1 billion under management and administration. Schenkelberg serves on the board of directors for MyImmunome, a biotech company focused on immune monitoring and diagnostics. He also has served on the board of directors for the African Services Committee in New York City, the largest U.S. organization supporting African immigrants and asylum seekers.

Schenkelberg is a Visiting Scientist at the Harvard T.H. Chan School of Public Health. He has an M.P.H. in infectious disease from The Johns Hopkins Bloomberg School of Public Health, an M.B.A. from The University of Chicago Booth School of Business where he completed joint graduate work at the London School of Economics, and a B.A. with Honors from Grinnell College.